CRP and COVID-19: Hyperbaric oxygen therapy (HBOT) may help manage the inflammatory phase of COVID-19 while avoiding the delayed viral shedding caused by corticosteroids.[36,37] Recently, HBOT has been reported to decrease inflammatory responses to SARS-CoV-2, including serum levels of CRP, ferritin, and LDH in a small randomized controlled study.[38] In contrast, HBOT has 2 limitations; the one is that the efficacy of HBOT on the severity of respiratory failure in COVID-19 has not been confirmed prospectively.[38,39] The other is that most institutes have limited access to HBOT, including our hospital.